Life Sciences

The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

Life Sciences has been a core strategy of Frazier Healthcare Partners since the firm’s beginning in 1991. The Life Sciences team has partnered with exceptional entrepreneurs at all stages of therapeutics development, from company formation around preclinical therapeutics to later-stage rounds for specialty pharmaceuticals companies. Across all stages, the Frazier team looks for product-focused opportunities with the potential to significantly advance patient care through innovation.

By the numbers as of Q4 2018

  • 500+ collective years of investing and operational experience
  • 95 portfolio companies
  • 58 M&As and IPOs
  • 26 approved drugs since 2010
Exceptional Entrepreneurs

Exceptional Entrepreneurs: James Ge and Vernon Jiang, addressing the emerging threat of antibiotic resistance as co-founders of four Frazier Life Sciences portfolio companies developing novel antibiotics.

Life Sciences Team

The team has expertise across all areas of drug development and commercialization, including clinical design and execution, FDA and regulatory strategy, and marketing and sales strategies.

View Life Sciences Team

Selected Drug Approvals from Our Portfolio

View More